Progress in vaccination against cancer (PIVAC) 2001, Robinson College, University of Cambridge, UK.
Rees
Robert C
RC
Department of Life Sciences, Nottingham Trent University, Faculty of Science, Clifton Lane, Nottingham, NG11 8NS, UK, robert.rees@ntu.ac.uk
Pawelec
Graham
G
Müller
Ludmila
L
Robins
Adrian
A
D000818:Animals; D000912:Antibodies, Neoplasm / Q000096:biosynthesis; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000637:transplantation; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007157:Immunologic Surveillance; D007167:Immunotherapy / Q000379:methods / Q000639:trends*; D008545:Melanoma / Q000276:immunology / Q000628:therapy; D051379:Mice; D008822:Mice, Transgenic; D009154:Mutation; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D015514:Oncogene Proteins, Fusion / Q000276:immunology; D014611:Vaccination / Q000639:trends*
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D006680:HLA Antigens; D015514:Oncogene Proteins, Fusion